

CTB2 Biorepository

IDENTIFYING TB BIOMARKERS, ACCELERATING TREATMENTS

CTB2 is a collaborative biobank accelerating development of new TB cures by identifying and validating biomarkers of response to TB drug treatments.

- 1,000 Newly-diagnosed TB patients contributing 300,000 biospecimens to long-term storage
- Samples & clinical data provided at 7 scheduled times; baseline through 12 months post-treatment, plus at recurrence/withdrawal
- Samples provided:
 - RNA from whole blood (PAXgene);
 - QuantiFERON from whole blood (QFT nil, mitogen, TB antigen)
 - Sputum
 - Urine
 - Plasma



www.tbbiorepository.org

Email: tbbiorepository@tballiance.org

Deadline for next submission: May 5, 2017

CTB2 is supported by:



BILL & MELINDA
GATES foundation



National Institute
of Allergy and
Infectious Diseases

CTB2 is comprised of:

